Dr. Wang on Future Research With CAR T-Cell Therapy in MCL
In Partnership With:
Michael Wang, MD, discusses the importance of additional CAR T-cell therapy research in mantle cell lymphoma.
Michael Wang, MD, a professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses the importance of additional CAR T-cell therapy research in mantle cell lymphoma (MCL).
CAR T-cell therapy is a new therapeutic modality in MCL, so additional research is needed, says Wang.
In the phase 2 ZUMA-2 trial, it was discovered that certain cytokines are associated with efficacy and toxicity, explains Wang. Moreover, future research efforts should aim to develop new measures that could enhance efficacy and minimize toxicity in these patients.
As the ZUMA-2 trial was relatively small, larger studies are necessary to obtain further insight on the utility of minimal residual disease, as well as cytokine profiling, Wang concludes.
